Interleukin-2 Inc. name change
Executive Summary
Alexandria, Va.-based R&D venture to go by name of Cel-Sci Corp. effective the first week of March following a shareholder vote Feb. 23. Depending on FDA's requirements, Phase I or Phase II studies of natural IL-2 involving 35 patients with advanced malignant melanoma will begin soon at the Melanoma Treatment Center, University of South Florida, College of Medicine. Results of Phase I/Phase II trials of IL-2 with 25 patients at St. Thomas' Hospital Medical School, London, England showed that the patients had an increase in lymphnode size and activity, which resulted in a reduction in tumor size.
|
Alexandria, Va.-based R&D venture to go by name of Cel-Sci
Corp. effective the first week of March following a shareholder
vote Feb. 23. Depending on FDA's requirements, Phase I or
Phase II studies of natural IL-2 involving 35 patients with
advanced malignant melanoma will begin soon at the Melanoma
Treatment Center, University of South Florida, College of Medicine.
Results of Phase I/Phase II trials of IL-2 with 25 patients
at St. Thomas' Hospital Medical School, London, England showed that
the patients had an increase in lymphnode size and activity, which
resulted in a reduction in tumor size. |